Introduction
============

In Greek mythology Perseus used his sword to strike off Medusa\'s head, probably because he anticipated that this would kill her immediately. The causal relationship between this injurious trigger and its immediate tissue consequences fostered the culture of executions in its various forms. So far only Victual Brother captain Klaus Störtebeker on (October 20th, 1401 in Hamburg) was reported to contradict that scenario after his beheading, when his body arose and he walked upright past 11 of his men to save them from being executed along with him.[@R1]

Most non-communicable diseases, however, arise from a mix of injury and the host\'s responses to it. Renal pathology, especially, is rather dominated by a complex process of tissue remodeling to which the injurious trigger accounts only partially and the kidneys get rather destroyed by the body\'s response to this trigger. But why did evolution develop processes that destroy our organs? Decisions during evolution are generally based on a careful risk-benefit assessment which implies that the processes that finally destroy kidneys provide some other significant survival benefits that outweigh renal damage. I will address this question by elaborating a unifying concept of (renal) pathology which is based on the following assumptions: (1) evolution has positively selected four major response programs to address the potentially life threatening dangers of traumatic injury from the state of primitive multicellular organisms, i.e., clotting, inflammation, epithelial and mesenchymal healing, (2) kidney remodeling results from deregulated danger response programs and (3) suppressing inflammation and promoting epithelial regeneration are the most promising approaches to prevent the loss of renal tissue, kidney remodeling and chronic kidney disease (CKD).

Danger Control after Trauma
===========================

Multicellular organisms need to maintain tissue integrity and any traumatic injury creates an immediate and potential fatal threat.[@R2] As such there is a need for sealing the wound and for tissue regeneration, a concept that applies to plants and animals.[@R3]^,^[@R4] Upon focal injury, danger responses control the problem locally, which is an important benefit to assure the survival of the entire organism. Survival outweighs the risk of any focal collateral damage that may be associated with these danger responses, e.g., focal immunopathology and scarring ([Fig. 1](#F1){ref-type="fig"}). The same concept applies to focal injuries to the kidney, such as biopsy injuries, infective pyelonephritis or even unilateral renal artery stenosis. However, nowadays many clinically common entities of kidney injury are of toxic, hemodynamic or metabolic nature, which hit both of the kidneys in all of their compartments. Nature has not yet developed (and probably will not in the future) different danger response programs to avoid the loss of solid organs that are absolutely necessary for survival. The reason for this is simple, even though it may be hard to accept for the renal scientist: renal failure was not (and probably never will be) a significant selection pressure for the survival of a species as a whole. Therefore, kidney tissue remodeling and renal failure in humans is an---from an evolutionary point of view---acceptable side effect of the otherwise very effective danger response programs that effectively assured the survival of multicellular organisms after traumatic tissue injuries.

![**Figure 1.** Traumatic injuries across species and kidney disease. Coordinated danger response programs are of benefit for multicellular organisms, even if they cause some collateral tissue damage or persisting defects. However, metabolic, hemodynamic or toxic factors rather hit the kidney in a diffuse manner which is why collateral damage affects the entire renal tissue and progresses to end-stage renal disease.](org-8-29-g1){#F1}

The Four Elementary Danger Response Programs in Skin Trauma
===========================================================

Wound healing after skin injury is a useful example to illustrate the four danger response programs in a temporal manner.[@R5]^-^[@R7]

Clotting
--------

Skin trauma usually induces bleeding which involves the potential risk of significant blood loss and hemorrhagic shock. Clotting, a complex interplay of the injured endothelial cells, the coagulation factors and platelet aggregation, represents the first danger response program that, within minutes, often perfectly controls this risk.[@R8] Insufficient clotting implies the risk for major bleedings, while overshooting clotting causes tissue ischemia via intravascular coagulation or thromboembolism.

Inflammation
------------

Eukarionts compete with prokarionts for nutritients and space of their biotope. This battle between eukarionts and prokarionts started from monocellular organisms and represents the underlying concept behind the evolution of the immune system and the clinical concepts of infectious diseases and host defense.[@R9] Traumatic injury of metazoan, such as skin wounding, involves the risk of pathogen entry and potentially fatal sepsis, a danger that has been addressed by rapid induction of a local inflammatory state that intends to control pathogen entry and spreading. Sponges and other primitive organisms use several hundreds of Toll-like receptors to recognize their microbial environment and to initiate inflammation and appropriate host defense mechanisms.[@R10]^-^[@R12] It is important to note that extrinsic pathogen-associated molecular patterns (PAMPs), as well as intrinsic damage-associated molecular patterns (DAMPs), can activate the same innate immunity pattern recognition receptor platforms which explains why infectious and sterile forms of inflammation initiate identical inflammatory responses.[@R13]^,^[@R14] Inflammation is already activated by clotting, as aggregating platelets release chemokines that trigger the recruitment of neutrophils and subsequently other leukocytes that attack, and ideally neutralize, pathogens.[@R15] Local inflammation and abscess formation support host survival while systemic inflammation during sepsis, a deregulated version of the same response program, implicates life-threating consequences.[@R16] Insufficient host defense implies the risk of potentially fatal infection while overshooting local inflammation causes unnecessary immunopathology and loss of parenchyma, e.g., in pyoderma gangraenosum.[@R17]

Epithelial healing
------------------

In wounds of non-sterile outer and inner surfaces the risk of infection can only be sufficiently controlled when the external barrier defect is rapidly repaired.[@R7]^,^[@R18] This is achieved by immediate signals that trigger re-epitheliazation from the borders of the wound.[@R4]^,^[@R7]^,^[@R19] Superficial erosions of the epidermis or the corneal and conjunctival epithelium heal rapidly also in adults.[@R4]^,^[@R7]^,^[@R19] Coagulation factors like fibrinogen and platelet-derived growth factors are the first mediators within the wound with direct mitogenic effects on surviving cells in the epithelial compartment.[@R4]^,^[@R8]^,^[@R15]^,^[@R19]^,^[@R20] During the inflammatory phase, epithelial growth factors, as well as certain interleukins like IL-6, IL-17 and IL-22, stimulate epithelial repair.[@R19]^,^[@R21]^-^[@R27] Epithelial healing depends on the presence of local progenitor cells that are committed to the specific epithelial lineage phenotype.[@R18]^,^[@R28]^,^[@R29] Progenitor-mediated re-epitheliazation should be a highly controlled and coordinated process requiring appropriate activation, proliferation, migration and finally differentiation into the final phenotype. Insufficient re-epitheliazation implies a persistent risk for infections and creates chronic wounds while overshooting or uncoordinated re-epitheliazation which causes hyperplastic wounds.[@R4]

Mesenchymal healing/fibrosis
----------------------------

Insufficient re-epitheliazation or injury to mesenchymal tissues activates the wound healing program of mesenchymal healing. This process stabilizes the organ structure, regrows vasculature or fills the gap of lost parenchymal cells that cannot regrow. After a bone fracture or a tear of a ligament, but also insufficient epithelial repair stimulates mesenchymal healing, e.g., through the process of epithelial-mesenchymal transition (EMT) of epithelial cells that get arrested in the G~2~/M phase.[@R30] The number of collagen-producing cells increases either by EMT,[@R31]^,^[@R32] by the influx of bone marrow-derived fibrocytes,[@R33]^,^[@R34] by the transition of pericytes or endothelial cells[@R34]^,^[@R35] or simply by proliferating resident fibroblasts and their transition to myofibroblasts.[@R35] The accumulation of extracellular matrix, i.e., fibrosis, leads to stiffening of the tissue, i.e., sclerosis. Insufficient mesenchymal healing may destabilize tissues and result in chronic wounds, while overshooting mesenchymal healing produces keloid and scleroderma.

The sequential activation of these danger response programs has been, and still is, essential to assure the survival of multicellular organisms so that they can reach the age of reproduction. Children and adolescents have to survive many skin wounds until the next generation is born; wound healing is also necessary to survive a baby's delivery. Given the enigmatic importance of these danger response programs it comes as no surprise that injuries to internal organs involve the activation of the identical series of mechanisms.

Clotting in Renal Pathology
===========================

There are several renal disorders that directly relate to clotting disorders such as the thrombotic microangiopathies or phospholipid antibody syndrome, which originate from intense activation of the endothelia.[@R36]^,^[@R37] Microvascular clotting causes tissue ischemia and eventually necrosis ([Table 1](#T1){ref-type="table"}). Vascular damage with GBM perforations and plasma leakage also occurs in intense tissue inflammation, e.g., in crescentic glomerulonephritis.[@R38] Vascular damage implies bleeding, which manifests as hematuria in the kidney, a process that should activate clotting. It is well documented that crescentic glomerulonephritis is associated with glomerular fibrinogen deposition especially in the area of loop necrosis.[@R39]^,^[@R40] The same applies to vascular disintegration in Alport nephropathy which lacks glomerular inflammation but where the genetic GBM abnormality promotes vascular injury.[@R41] Activated platelets release coagulation factors as well as proinflammatory and mitogenic factors which activate inflammation and epithelial healing, e.g., CC-chemokines, platelet-derived growth factors (PDGF) and others.[@R8]^,^[@R15]^,^[@R19]

###### **Table 1.** Danger response programs and typical histopathologic abnormalities of the kidney

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Program               Insufficient                 Predominant
  --------------------- ---------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Clotting              Macrohematuria               Thrombotic microangiopathy\
                                                     Ischemic necrosis

  Inflammation          Pathogen-related pathology   Immunopathology, necrosis, apoptosis, necroptosis (renal abcess formation, crescentic glomerulonephritis, allograft rejection, interstitial nephritis, acute tubular necrosis)

  Epithelial healing    FSGS, glomeruloscerosis\     Crescentic glomerulonephritis\
                        Tubular atrophy              Podocytes pushed into catastrophic mitosis\
                                                     Cyst formation, chronic vasculopathies

  Mesenchymal healing   Mesangiolysis                Mesangioproliferative glomerulonephritis Glomerulosclerosis\
                                                     Interstitial fibrosis, hypertensive vasculopathy
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Insufficient or Overshooting Inflammation in Renal Pathology
============================================================

Renal inflammation is a major determinant of AKI, as well as the progression of CKD. The network of resident dendritic cells inside the kidney and infiltrating mononuclear phagocytes are fully equipped with the entire spectrum of pattern recognition receptors that can activate innate immunity.[@R42]^,^[@R43] In addition, the renal parenchymal cells express a limited spectrum of such receptors.[@R44]^,^[@R45] Mesangial cells, endothelial cells, podocytes, tubular cells and renal fibroblasts lack some of the endosomal nucleic acid-specific Toll-like receptors and the NLRP3 inflammasome but they readily get activated by exposure to bacterial endotoxin and other PAMPs and DAMPs.[@R46]^,^[@R47] For example, infections cause a transient exposure to PAMPs that have the potential to activate cells and trigger inflammatory responses inside and outside the kidney. We have demonstrated this concept by transiently injecting agonists into mice with experimental immune complex glomerulonephritis or lupus nephritis and could demonstrate that they activate the intrarenal production of cytokines, type I interferons which increases inflammation and tissue damage.[@R48]^-^[@R58] By contrast, the NLRP3 inflammasome contributes to interstitial, but not to glomerular, disease.[@R59]^-^[@R61] The type of response depended on the cell-type specific expression of the involved receptors which explains the heterogeneity of infection-associated flares of, e.g, IgA nephropathy, lupus nephritis and renal vasculitis.

Another important aspect of PAMP-mediated renal inflammation is the loss of renal parenchymal cells, especially podocytes, because these cannot be easily regenerated. When mice with Alport nephropathy were transiently injected with bacterial CpG-DNA, resident dendritic cells and infiltrating Ly6Chigh^+^ macrophages were stimulated to produce more proinflammatory mediators including the proapoptotic cytokine tumor necrosis factor-α which induced podocyte apoptosis and accelerated progressive glomerulosclerosis.[@R62]

Renal inflammation does not only result from extrinsic stimuli. Any kind of tissue damage that causes renal cell necrosis can cause the release of DAMPs from intracellular compartments, which signals "danger" to the innate immune system.[@R44]^,^[@R63]^,^[@R64] For example, renal ischemia-reperfusion injury does not involve PAMP exposure but tubular cell necrosis induces a TLR-dependent acute intrarenal inflammatory response which largely contributes to the extent of AKI and loss of renal function.[@R65]^-^[@R68] Surprisingly, TLR signaling occurs mostly in renal parenchymal cells[@R44] because TLR signaling in the intrarenal network of dendritic cells is efficiently suppressed by the constitutive and induced expression of TLR signaling inhibitors thatare absent or dysfunctional in tubular epithelial cells.[@R69]^-^[@R72] As another example, lupus nephritis is a state of abnormal immune recognition of endogenous nucleic acids.[@R73]^,^[@R74] Nuclear particles that contain immunostimulatory endogenous RNA and/or DNA activate antigen-presenting dendritic cells, macrophages, and B cells, to mature and to release numerous proinflammatory mediators including type I interferon.[@R74]^,^[@R75] The latter set off a coordinated antiviral immune response explaining the similarities between the clinical manifestations of viral infections and systemic lupus.[@R76] This process also occurs inside the kidney as documented by the antiviral gene expression signature in renal biopsies.[@R77]^,^[@R78] For example, mesangial cells and glomerular endothelial cells use their cytosolic nucleic acid sensors to translate nucleic acid recognition into the release of type I interferons which contribute to renal inflammation and tissue damage.[@R79]^-^[@R84]

Innate immune activation triggers the local release of cytokines and chemokines which attracts various subsets of leukocytes into the kidney.[@R85]^-^[@R88] Macrophages, T cells and B cells occur in different subsets that all differently contribute to the regulation of inflammation and renal immunopathology.[@R89]^,^[@R90] Activating intrarenal macrophages, e.g., by transient infections or certain drugs, can turn non-activated into activated leukocytes which strongly contribute to renal pathology.[@R91]^-^[@R93] Blocking the recruitment of pro-inflammatory macrophages by interfering with the CC-chemokine CCL2 or its receptor CCR2 probably reduces renal immunopathology in the glomerular as well as the tubulointerstitial compartment in those diseases that are associated with renal inflammation, but not in non-inflammatory forms like Alport nephropathy.[@R94]^-^[@R99] However, TLR-mediated renal inflammation remains an important element of pathogen control in renal infections. For example, BK virus infection of the allograft requires TLRs and cytosolic nucleic acid receptors to translate pathogen recognition into appropriate antiviral host defense.[@R100] The enigmatic importance of renal inflammation also becomes evident during bacterial pyelonephritis.[@R101] Insufficient pathogen recognition and renal inflammation will allow pathogen overgrowth and pathogen spreading, which holds the risk of systemic infection. For example, mice that lack a functional LPS receptor, i.e., TLR4, and that are inoculated with uropathogenic *E. coli* into the urinary bladder, are protected from renal abscess formation because they can no longer recognize *E. coli* LPS and lack the appropriate chemokine signaling that would be required to recruit neutrophils into the infected kidneys.[@R102] This apparent protection from immunopathology occurs at the price of insufficient pathogen control at the entry site and could cause fatal bacterial spreading across the entire organism.

Together, the kidney is mostly a sterile organ in which pathogen control, the evolutionary rationale for inducing innate immunity, remains a rare event. As such, the kidney is mostly affected by renal inflammation that is triggered by remote infections that release immunostimulatory elements into the circulation or by intrarenal release of DAMPs that promote a sterile inflammatory response which predominately promotes unnecessary (collateral) damage to renal cells, a useless atavism of wound healing ([Table 1](#T1){ref-type="table"}). Thus, suppressing renal inflammation should be a valid strategy to preserve renal tissue, especially renal epithelial cells and vasculature. Drugs with anti-inflammatory properties without systemic immunosuppressive effects may be sufficient for that.[@R103] The protection of podocytes from unnecessary inflammatory stress is of major importance because lost podocytes can hardly be regenerated and the subsequent glomerulosclerosis still accounts for the majority of CKD cases.

Insufficient or Overshooting Epithelial Healing in Renal Pathology
==================================================================

In the glomerulus as well as within the tubules the epithelial cells are of enigmatic importance to the specific function of the compartment. After a transient and short-term ischemic or toxic tubular injury sufficient epithelial repair can rapidly restore renal function.[@R104]^,^[@R105] Numerous growth factors drive the repair of the epithelial monolayers after injury.[@R19] For example, PDGF is already released by platelets or injured epithelia during the early phase of injury.[@R8]^,^[@R15] BMP-7 and its receptor activin-like kinase-3 also contribute to epithelial healing.[@R106] Furthermore, cell cycle regulators like murine double minute (MDM)-2 assure the proliferative response during AKI by inhibiting p53-dependent cell cycle arrest.[@R107] Epithelial healing becomes more evident after the down-modulation of intrarenal inflammation.[@R108] The removal of necrotic cells and their DAMPs by infiltrating phagocytes changes the renal microenvironment which promotes a phenotype shift of the intrarenal mononuclear cells toward anti-inflammatory and pro-regeneratory phenotypes.[@R90] This process is associated with the release of additional growth factors that drive epithelial repair in the kidney (and the liver).[@R108]^-^[@R111] A persistent activation of intrarenal mononuclear cells toward proinflammatory phenotypes, e.g., due to aberrant genetic macrophage priming such as IRAK-M deficiency (own unpublished data) or repetitive/persistent triggers of kidney injury impair this epithelial healing response. In addition, severe forms of kidney injury may also kill the epithelial progenitor cells which are located within the renal epithelial monolayer and that have a higher capacity to survive stress.[@R112] Even though it was clearly demonstrated that renal epithelial cells repair without a cellular contribution from bone marrow stem cells, the contribution of local progenitor cells vs. epithelial renewal from differentiated tubular epithelial cells to tubular repair from inside the tubular compartment remains under debate.[@R113]^-^[@R117] However, it is obvious that an insufficient repair of the tubular epithelial monolayer will lead to tubular atrophy and nephron loss, a typical characteristic of progressive CKD ([Table 1](#T1){ref-type="table"}).

Insufficient epithelial repair in the glomerular compartment is the predominant cause for CKD. The particular structure of the differentiated podocyte which is required to fulfill its important function at the glomerular filtration barrier remains a major obstacle for rapid repair.[@R118]^-^[@R120] There has been a controversial debate regarding whether bone marrow-derived progenitors are able to replace lost podocytes.[@R121]^-^[@R123] It has now been convincingly demonstrated that podocytes originate from local epithelial progenitors at the urinary pole of the glomerulus that can migrate to the vascular pole and differentiate into terminally differentiated podocytes on the glomerular tuft.[@R124] This process clearly operates during renal development and early childhood[@R101] but its capacity to replace injured podocytes seems to be limited in adult mice.[@R125]^,^[@R126] The mechanisms that regulate podocyte renewal within the epithelial monolayer of glomerular visceral and parietal epithelial cells are still poorly understood. There is increasing evidence that those factors that regulate other stem cell compartments, such as Notch and Wnt signaling, EGF and SDF-1/CXCL12 also regulate podocyte renewal from their local progenitors.[@R127]^-^[@R130] Particularly, heavy proteinuria seems to suppress podocyte repair because glomerular diseases that are associated with nephrotic syndrome show the highest tendency to progressive glomerular scarring, i.e., glomerulosclerosis.[@R131]^,^[@R132] This process is associated with specific epigenetic imprinting at histone H3K9, H3K23 (acetylation), H3K4 (dimethylation) and H3K4 phosphorylation at serine 10 which alters gene expression and cell growth.[@R133]^,^[@R134]

Overshooting epithelial repair also exists in the kidney, especially when the epithelial cells at the progenitor cell location get heavily activated in the absence of the necessary signals for differentiation.[@R112]^,^[@R135]^,^[@R136] For example, rapid progressive glomerulonephritis combines glomerular vascular damage and fibrinogen activation with intense intraglomerular inflammation.[@R128]^,^[@R137]^,^[@R138] All these factors heavily activate parietal epithelial cells to proliferate without any apparent differentiation into podoctes.[@R41]^,^[@R136] Upon rupture of Bowman's capsule infiltrating macrophages and T cells provide additional stimuli for the proliferation of epithelial cells.[@R137]^,^[@R138] We used the model of *Col4A3*-deficient mice in the 129/X1/SvJ genetic background to study crescent formation in the absence of glomerular inflammation. Disruption of glomerular capillaries causes plasma leakage which is sufficient to trigger the uncoordinated proliferation of parietal epithelial cells, a cell type that normally resides, devoid of serum contact, in the urinary space.[@R41]

Overshooting epithelial healing in the tubular compartment is less evident. The tubular progenitor cells are located at the junction of glomeruli and proximal tubules while single progenitor cells are scattered in the proximal and distal tubules of the cortex.[@R139] Chevalier, et al. have recently demonstrated that the phenomenon of atubular glomeruli originates from an obstruction of the tubular lumen by epithelial cells.[@R140]^,^[@R141]

Together, epithelial repair is an important element to regain homeostasis after injury. Insufficient epithelial repair is the central element of glomerulosclerosis and tubular atrophy. Overactive epithelial repair can cause other forms of renal pathology, i.e., glomerular crescents. It should be desirable to stimulate a coordinated proliferation and differentiation of surviving epithelial cells of their local progenitor cells.

Mesenchymal Healing in Renal Pathology
======================================

Tissue healing is not limited to epithelia. Bleeding (skin) wounds imply damage to mesenchymal structures. Neo-angiogenesis, bone fractures, ligament ruptures or muscle damage require mesenchymal healing. In addition, healing in general implies the need for mechanical stabilization also of parenchymal tissues like the kidney, i.e., epithelial growth factors are secreted together with pro-fibrotic growth factors that stimulate the mesenchymal cells of the tissues to mature and to increase the secretion of extracellular matrix.[@R19] For example, in skin wounds resident tissue fibroblasts are activated to mature to myofibroblasts that produce type I and other collagens and to promote wound contraction which reduces the wound area, a process that limits infections and that supports re-epithelisation.[@R4] In areas of irreversible tissue loss, e.g., after ligament rupture or severe burning of the skin, fibrous tissue fills the gap of the lost tissue. In the long run, fibrolysis, the process of removing fibrous tissue after the disease process has ended, leads to a reduction of scar size to the minimum of what is absolutely required to stabilize the tissue.[@R4] These outstanding beneficial effects of mesenchymal healing should not be forgotten when questioning why many different renal disorders lead to a common scarring pathway. Again, during evolution the benefits of fibrosis outweigh the problems which, however, can become the predominant problem of few individuals. For example, the contraction of the fibrous skin wounds of badly injured skin can reduce joint mobility which, still, remains a focal problem. In the kidney, again, the diffuse nature of metabolic, hemodynamic, and toxic injuries implies that the process of fibrosis affects all of the kidney tissue to the same extent ([Table 1](#T1){ref-type="table"}). In this context, wound contraction implies the development of shrunken kidneys. However, it is likely that fibrosis itself does not destroy the kidney. The extracellular matrix mainly replaces lost renal epithelia. As such, reducing fibrosis may result in even smaller kidneys, if not accompanied by regeneration of intact nephrons. For example, repetitive mesenchymal stem cell injection into *Col4A3*-deficient mice with progressive Alport nephropathy significantly reduced interstitial fibrosis of the kidney but did not improve renal function and overall survival.[@R142] Renal interstitial fibrosis, even though an extremely interesting process with multiple fascinating aspects to study with the latest technologies,[@R32]^,^[@R35]^,^[@R143] rather seems to be a marker of loss of renal parenchyma rather than a pathogenic factor of renal failure by itself. It is of note that the driving factor of interstitial fibrosis seems to be an insufficient epithelial repair, e.g., when proliferating epithelial cells get arrested in the G~2~/M phase and start to produce tumor growth factor-β,^30^ a process, e.g., also triggered by aristocholic acid,[@R30]^,^[@R144] the pathogenic element of Chinese herb nephropathy.[@R145] This concept implies that in the kidney mesenchymal healing could be a second-line healing program that predominates whenever epithelial healing is too slow or of low capacity.

This certainly applies for the glomerular compartment because podocyte renewal from local progenitors is mostly insufficient, especially in proteinuric disorders of the adult.[@R112]^,^[@R132] Smeets et al. have recently demonstrated that in FSGS parietal epithelial cells do not sufficiently differentiate into mature podocytes but rather increase the production extracellular matrix.[@R146] Ideally, this scar formation stabilizes the glomerular pathology by forming a stable synechia or focal scar, like it may happen in some forms of secondary focal-segmental glomerulosclerosis. However, when a higher percentage of glomerular podocyte gets lost, the scarring process has its own dynamic, and rapidly progresses to global glomerulosclerosis,[@R120] mostly because the hyperfiltration of the remaining glomerular loops puts additional dynamic stress on the initially unaffected podocytes.[@R118]^,^[@R147] A mesenchymal transition of parietal epithelial cells also contributes to the formation of fibrocellular crescents.[@R148] We recently documented that crescent formation in *Col4A3*-deficient mice with Alport nephropathy is associated with a phenotype switch of the proliferating parietal epithelial cells.[@R41] Parietal cells in cellular crescents lose their epithelial polarity and start to produce extracellular matrix into all directions like mesenchymal cells which leads to the honeycomb-like transformation of the Bowman\'s space into fibrocellular crescents.[@R41] This process is conceptually similar to the epithelial-mesenchymal transition of tubular epithelial cells which is thought to contribute to the heterogeneity of interstitial fibroblasts.[@R35] The significance of this phenomenon for human kidney disease remains under debate because clear evidence is still lacking that the transformed epithelial cells actually leave the tubular compartment by passing through their tubular basement membrane in vivo.[@R32]^,^[@R149]^-^[@R151] In the glomerulus, however, parietal epithelial cells that do not adequately differentiate into podocytes clearly undergo this mesenchymal transition and cause scarring without leaving their compartment.[@R41]^,^[@R148]

Infiltrating leukocytes and other bone marrow progenitors contribute to renal fibrosis, as reducing leukocyte recruitment markedly reduces interstitial fibrosis in various models of glomerular or tubulointerstitial kidney disease.[@R85]^,^[@R152]^-^[@R155] Whether this is a direct or an indirect effect is less clear.[@R99]^,^[@R156]^,^[@R157] For example, blocking or deletion of the chemokine receptor CCR1 prevents the recruitment of alternatively activated macrophages with a "wound healing" phenotype which can modulate the fibrotic process directly.[@R90]^,^[@R158]^-^[@R165]

Together, mesenchymal repair is an important element to stabilize tissues after traumatic injury, especially after loss of parenchymal tissue. In the kidney, insufficient scarring does not seem to be a problem. Glomerular scarring, glomerulosclerosis and the formation of fibrocellular crescents, is the greatest concern because of their irreversible nature and the missing capacity to regrow lost nephrons. Why scarring does not occur inside the tubular compartment remains a miracle, but the interstitial compartment is commonly affected. Fibroblast activation and matrix deposition seem to fill the gaps left by dying nephrons. However, because nephrons do not grow back, this mechanical stabilization of the renal tissue is another useless atavism and the contraction of the fibrous tissue further contributes to kidney shrinking. Whether reducing renal fibrosis alone can regain renal function without replacing the lost nephrons remains under debate.

Summary
=======

Traumatic tissue injury endangers the survival of multicellular organisms, hence, a series of danger response mechanisms were positively selected throughout evolution. Clotting and inflammation prevent bleeding and infection and are followed by epithelial and mesenchymal healing for tissue repair. During focal injuries these responses assure survival even when collateral damage leads to persistent defects such as focal immunopathology and scarring. The kidneys, however, are mostly affected by toxic, metabolic, hemodynamic or immune-mediated triggers of injury which affect all parts of both kidneys at the same time. Therefore, clotting and inflammation, as well as abnormal healing responses, often trigger remodeling of the renal tissue and promote additional and potentially progressive kidney injury. From a therapeutic perspective, the inhibition of renal inflammation together with the stimulation of epithelial healing without promoting mesenchymal healing should be the most promising strategy.

Dr Jeffrey Miner, Professor of Medicine, Washington University School of Medicine:
----------------------------------------------------------------------------------

Do you know when in the Alport disease the proliferative response begins? When can you first detect Ki67 positive podocytes or parietal cells?

Dr Hans-Joachim Anders, Professor of Medicine, Klinikum der Universitat Munchen:
--------------------------------------------------------------------------------

We noticed crescents already at early stages of the disease. Within weeks there are global crescents. Then later crescents become more prominent. We have not really tried to find out what is the earliest time point when that starts. There is quite some variability also on that point. In the end as you saw, the mortality curve is quite tight. The mice more or less died between 8 and 10 weeks of age.

Dr Miner:
---------

My immunologist colleagues tell me that LPS induces TNF α expression by the liver such that it can explain all of the downstream effects. Are you saying that it must be produced within the kidney to have the effects that you are seeing?

Dr Anders:
----------

It was an unexpected finding for us to see that repetitive LPS injections did not do anything to impact the progression of Alport nephropathy. Of course, then we focused more on the positive finding on the CpG-DNA, so we did not really follow-up on the question, why didn't we see anything with LPS. The easiest explanation would be that the repetitive injections were more or less turning down the system. Which should also work somehow with CpG-DNA but it is far less dominant because the LPS receptor TLR4 is expressed in all cells, also inside the kidney. Whereas the receptor for CpG-DNA is only expressed on the immune cells, on B cells and macrophages of which we mainly find the macrophages inside the kidney of Alport mice. So we think with that we mainly modulated the inflammatory component that comes from the macrophages. Whereas, one would have expected that, because the receptors are everywhere, the effect of LPS would be much stronger, so the only explanation I have is that it is a downregulatory effect that starts from the second injection.

Dr Miner:
---------

Did you try combining the LPS with the CpG-DNA?

Dr Anders:
----------

No.

Dr Helen Liapis, Professor of Pathology and Immunology and Medicine, Washington University School of Medicine:
--------------------------------------------------------------------------------------------------------------

I would like you to expand on your concept about environmental dangers. In the Alport case, what do you think may be an environmental danger response in humans who carry an inherited mutation and how that will work with your concept.

Dr Anders:
----------

I mean, we used agonists for bacteria and injected them systemically. So from that point of view one would conclude that at least systemic infections should provide that kind of stimulus to promote the progression of the disease. We have done a lot like that in lupus models where you clinically already have the experience that infections could cause a flare. We did the same kind of studies in lupus mice and were injecting all different kinds of Toll-like receptor agonists and then carefully described how does the flare develop and that may be related to the cell-type specific expression of the Toll-like receptors in the end.[@R14]^,^[@R93] From there we knew that it is really the cells inside or outside the kidney get stimulated by that particular agonist and then you get more inflammation. In Alport\'s you anyway have a low grade of inflammation and the inflammation increases only upon a particular stimuli. I would raise the hypothesis, that infections are no good for Alport kids or any people with CKD, with a smoldering disease process and that any infection that would transiently activate innate immunity could then increase cytokine release and attract more leukocytes, and cause more kidney damage. I think the clinical experience from IgA nephropathy is pretty clear, that you have even vascular ruptures causing macrohematuria in association with an infection which then goes away after a while. Those of you who see lupus patients or patients with renal ANCA vasculitis know very well that each flare takes away some part of the renal function and that flares are indicators of bad outcomes.

Dr Liapis:
----------

Are there any data on TNF in humans or in the serum in patients with Alport?

Dr Anders:
----------

Not that I know. No one has looked at it.

Dr Feng Chen, Associate Professor of Medicine, Washington University School of Medicine:
----------------------------------------------------------------------------------------

You mentioned that scars occur in tubular injury because the repair may come too slowly. That certainly is the case. In the glomerulus, proliferation at a high rate may also cause problems like the loss of polarity. For the parietal cells to replace the damaged podocytes, they have to migrate a long distance in order to reach the correct location for repair. Is it possible that for optimal repair of the glomerulus, it might be better to slow down the proliferation? Maybe slower is better in this case.

Dr Anders:
----------

Yes, we actually do that in renal vasculitis by treating the patient with cyclophosphamide so we reduce the proliferation. Repair mechanisms have their good and bad sides. It is well known that an overgrowth of bone marrow stem cells can lead to myeloproliferative syndromes and if bone marrow stem cells don't proliferate enough you get myelodysplastic syndromes. That means you need a coordinated proliferation of those cells to maintain homeostasis. If it is too few it can cause problems. If it is too much it can also cause problems. Now that the cells have been identified, I think it is pretty clear that, for example FSGS is a disease, where the podocyte repair is insufficient. There is loss of podocytes and somehow the podocyte progenitors within the parietal epithelial cell compartment cannot compensate that and that is why you end up with a scar. If you have crescentic disease you get dramatic activation of this regenerative response. That is why you get a crescent. What we need is that repair happens in a coordinated manner and I think you can imagine that if you have a progenitor which is quiescent it first needs to be activated. We saw that WT-1 gets induced, which means these cells get activated toward a podocyte phenotype. Then they should proliferate first and then migrate and when it arrives at the glomerular tuft it should differentiate into a podocyte. You need those four steps to happen in a coordinated way. Let's just imagine that if you have a vascular lesion like in ANCA vasculitis you have a dramatic inflammation of the glomerulus, vascular disruption, you have seen the picture by Steve Bonsib. You get serum leakage, these cells get heavily activated to proliferate but not to differentiate to the same extent. That means you get an overgrowth of undifferentiated progenitors, you get a crescent. That is probably what happens and somehow in FSGS you get podocyte loss. There is proteinuria. The progenitor cells should get activated but somehow they don't proliferate as they should or a least they don't differentiate. I think Marcus Moeller has shown, just a few months back, very nicely, that the parietal cell makes the scar in FSGS.[@R146] The cells go there but then they are unable to differentiate so they stay there and they use the second program, they produce matrix and that is why you end up with a scar. This work raises the idea that many of the diseases that we see relate to an over stimulation or blockade of the intrinsic capacity of the kidney to repair itself.

Dr Ying Maggie Chen, Assistant Professor of Medicine, Washington University School of Medicine:
-----------------------------------------------------------------------------------------------

The GBM gaps are caused by matrix metalloproteinase (MMP) digestion, right? Is MMP mainly produced by macrophage cells or by podocytes because podocytes can also upregulate MMP expression?

Dr Anders:
----------

The published data are more in support of that MMP12 is released from macrophages.[@R166]

Dr Y.M. Chen:
-------------

Regarding the animal model, you are using collagen IV α 3 knockout mice on the genetic background of SV129, which develops Alport much faster than another genetic background. Would you think that the findings on SV129 can be replicated in another genetic background?

Dr Anders:
----------

That is a good question. We thought about this but could not find a reason to do the experiment because we were mainly using that as a model so that means we needed crescents to ask the question: how do they develop? Dr. Liapis had looked at human Alport cases and were able to find only very few crescents. There are a small number of papers describing crescent also in human Alport but, at least, in this cohort it was less than 1%.[@R41] So that means, I think it is not so interesting to find out whether it also happens in another mouse, if it is not a big problem in humans. I would think that certainly the genetic background plays an important role here.

Dr Marc Hammerman, Chromalloy Professor of Medicine, Washington University School of Medicine:
----------------------------------------------------------------------------------------------

Are there any circumstances in humans or in mammals in which we have evidence that renal repair is accomplished on the basis of stem cell migration and differentiation or does this only apply in fish?

Dr Anders:
----------

Marcus Moelle was able to trace the parietal cells that were stained in blue in his mouse then move on the tuft.[@R125] It was published in the same JASN edition along with the paper of Paola Romagnani demonstrating that parietal cells harbour renal progenitor cells. Her data were all generated in humans.[@R124] Markus data were generated in the mouse.[@R125] He was able to show that this happens mostly in young but no longer in older mice. From that the idea arises that maybe the capacity to regrow podocytes from progenitors is much higher in kids than in adults and from that you can speculate a lot. For example, why FSGS is much more frequent in adults than kids or minimal change diseases almost never ends up in scarring in kids. So that could mean that kids maintain a higher capacity to repair damaged podocytes from their local progenitors. And with aging this capacity gets lost somehow. We still don't know the reasons and why adults much more frequently end up with FSGS a podocyte injury. There are no data yet to support that. These papers were published 2 years back, I think now many people move into this field and each of them with different questions then hopefully in a few years we will be able to get answers to these questions.
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